Mithra jumps on positive menopause drug study, mgmt pipeline comments

Mithra Pharmaceuticals SA

06/03/2023 08:27

** Shares in Mithra Pharmaceuticals  MITRA.BR  rise about 7%
after it reported positive safety results for its menopause
effects drug Donesta
    ** The Phase 3 study evaluated the efficacy and safety of
Donesta for the treatment of vasomotor symptoms in
post-menopausal women, with positive results to support the
filing with U.S. regulatory agency for market authorisation
    ** "A leap of strength by Mithra with several news items, as
the Board steps in with resolute actions to stop the recent
share price freefall," KBC Securities says, adding it expected
the positive study outcome but is glad to see it confirmed
    ** Mithra's board confirmed in a separate statement it will
move forward on its proprietary inhibitors of CSF-1R potential
to treat different pathologies and to "optimise" the potnetial
of its R&D platform CDMO
    ** The decisions "pave a road ahead for the company,
confirming CSF-1R as next pipeline opportunity, a seemingly
implied exit of the CDMO", KBC adds
    ** The stock is heading for its best day in seven months if
gains hold

 (Reporting by Piotr Lipinski)
 ((piotr.lipinski@tr.com))